ArticleArthritis & rheumatology (Hoboken, N.J.)2018
Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 114 citations in OpenAlex.
- A transcriptional patient map of systemic lupus erythematosus reveals disease-related multicellular immune programs conserved between blood and kidney.bioRxiv : the preprint server for biology · 2026Article
- Assessing the translational relevance of specific molecular pathways in spontaneous lupus mouse models.Frontiers in immunology · 2026Article
- PBLD Orchestrates the STING-Mediated Antiviral Immune Response and Autoimmune Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of STAT3 signaling as a shared pathogenic signature in systemic lupus erythematosus, chronic obstructive pulmonary disease, and asthma.Scientific reports · 2025Article
- Article
- Prognostic insights from symptom clustering analysis in systemic lupus erythematosus.RMD open · 2025Article
- How artificial intelligence can enable personalized mesenchymal stem cell-based therapeutic strategies in systemic lupus erythematosus.Frontiers in immunology · 2025Review
- Association of autoantibodies with the IFN signature and NETosis in patients with systemic lupus erythematosus.Journal of translational autoimmunity · 2024Article
- The molecular subtypes of autoimmune diseases.Computational and structural biotechnology journal · 2024Review
- Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE.Cell reports. Medicine · 2024Article
- Identification of EPSTI1 as a new potential biomarker for SLE based on GEO database.Clinical rheumatology · 2024Article
- Platelet TLR7 is essential for the formation of platelet-neutrophil complexes and low-density neutrophils in lupus nephritis.Rheumatology (Oxford, England) · 2024Article
- Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis.JCI insight · 2024Article
- In cis "benign" SOCS1 variants linked to enhanced interferon signaling and autoimmunity.Journal of autoimmunity · 2023Article
- Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications.Genome medicine · 2023Article
- Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE.medRxiv : the preprint server for health sciences · 2023Article
- Application of Machine Learning Models in Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Review
- Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders.Cambridge prisms. Precision medicine · 2023Review
- Molecular mechanisms governing the progression of nephritis in lupus prone mice and human lupus patients.Frontiers in immunology · 2023Article
- Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal study.Rheumatology (Oxford, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
objectiveThe highly heterogeneous clinical presentation of systemic lupus erythematosus (SLE) is characterized by the unpredictable occurrence of disease flares and organ damage. Attempts to stratify lupus patients have been limited to classification based on clinical information, leading to unsuccessful clinical trials and controversial research results. This study was undertaken to develop and validate a robust method to stratify patients with lupus according to longitudinal disease activity and whole-genome gene expression data in order to establish subgroups of patients who share disease progression mechanisms.
methodsWe used a cluster-based approach to stratify SLE patients based on the correlation between disease activity scores and longitudinal gene expression information. Clustering robustness was evaluated by the bootstrap method, and the clusters were characterized in terms of clinical and functional features.
resultsWe observed a clear partition into 3 different disease clusters in 2 independent sets of patients, one pediatric and one adult, which was not influenced by treatment, race, or other source of bias. Two of the clusters differentiated into a group showing a correlation between the percentage of neutrophils and disease activity progression and a group showing a correlation between the percentage of lymphocytes and disease activity progression. The third cluster, in which the percentage of neutrophils correlated to a lesser degree with disease activity, was functionally more heterogeneous. Patients in the neutrophil-driven clusters had an increased risk of developing proliferative nephritis.
conclusionOur findings indicate that SLE patients can be stratified into 3 subgroups of patients who show different mechanisms of disease progression and are clinically differentiated. Our results have important implications for treatment options, the design of clinical trials, our understanding of the etiology of the disease, and the prediction of severe glomerulonephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.